511509 VIVOBIOT

Vivo Bio Tech Share Price

 

 

Start SIP in VIVOBIOT

Start SIP

Performance

  • Low
  • ₹31
  • High
  • ₹32
  • 52 Week Low
  • ₹25
  • 52 Week High
  • ₹56
  • Open Price₹32
  • Previous Close₹32
  • Volume13,186
  • 50 DMA₹31.73
  • 100 DMA₹33.21
  • 200 DMA₹35.01

Investment Returns

  • Over 1 Month + 17.61%
  • Over 3 Month -19.16%
  • Over 6 Month -12.44%
  • Over 1 Year -39.5%

Smart Investing Starts Here Start SIP with Vivo Bio Tech for Steady Growth!

Invest Now

Vivo Bio Tech Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 12.2
  • PEG Ratio
  • -0.3
  • Market Cap Cr
  • 50
  • P/B Ratio
  • 0.6
  • Average True Range
  • 1.73
  • EPS
  • -
  • Dividend Yield
  • 0
  • MACD Signal
  • 0.16
  • RSI
  • 49.49
  • MFI
  • 77.48

Vivo Bio Tech Financials

Vivo Bio Tech Technicals

EMA & SMA

Current Price
₹31.05
-0.69 (-2.17%)
pointer
  • Bearish Moving Average 14
  • Bullish Moving Average 2
  • 20 Day
  • ₹31.18
  • 50 Day
  • ₹31.73
  • 100 Day
  • ₹33.21
  • 200 Day
  • ₹35.01

Resistance and Support

31.37 Pivot Speed
  • R3 32.62
  • R2 32.30
  • R1 31.69
  • S1 30.76
  • S2 30.44
  • S3 29.83

Vivo Bio Tech Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-14 Quarterly Results
2025-08-12 Quarterly Results
2025-05-19 Audited Results
2025-01-09 Quarterly Results
2024-11-21 Employees Stock Option Plan

Vivo Bio Tech F&O

Vivo Bio Tech Shareholding Pattern

35.16%
32.3%
32.54%

Vivo Bio Tech FAQs

Vivo Bio Tech share price is ₹31 As on 11 January, 2026 | 00:14

The Market Cap of Vivo Bio Tech is ₹50.1 Cr As on 11 January, 2026 | 00:14

The P/E ratio of Vivo Bio Tech is 12.2 As on 11 January, 2026 | 00:14

The PB ratio of Vivo Bio Tech is 0.6 As on 11 January, 2026 | 00:14

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23